‘Nexavar has verified efficacy in kidney tumor and liver cancers and we are focused on researching Nexavar in a number of additional solid tumors,’ stated Dimitris Voliotis, MD, vice president, Nexavar Clinical Advancement, Bayer HealthCare. ‘Predicated on strong results in the Stage II trials, Bayer and Onyx relocated to another phase of advancement and initiated this Stage III trial analyzing Nexavar in NSCLC http://www.levardenafil.com http://levardenafil.com/ .’ About the Stage III Study The Objective trial can be an international multicenter research which will enroll approximately 850 individuals with advanced relapsed or refractory non-squamous cell NSCLC who’ve failed several previous treatments. Patients will be randomized to get either Nexavar as one agent or placebo.
BAY 73-4506 in addition has been proven in preclinical research to avoid the proliferation of tumor cell lines while advertising apoptosis by directly targeting many oncogenic TK receptors. The clinical need for these studies isn’t known and warrant additional investigation in a wide spectrum of tumors.. Bayer announces new data about novel anti-cancer compound Bayer today announced outcomes from Phase We and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor becoming studied in multiple tumor types. These data were provided at the 45th Annual Achieving of the American Culture of Clinical Oncology . Bayer is focused on discovering fresh cancer-fighting therapies, stated Kemal Malik, MD, Chief Medical Mind and Officer of Global Advancement at Bayer HealthCare.